Inflammatory response inhibition

"Inflammatory response inhibition" refers to the therapeutic strategy or biological outcome of suppressing one or more components of the body's innate and adaptive immune responses that drive inflammation. This can involve targeting various molecules—such as pro-inflammatory cytokines (TNF-alpha, IL‑1β), their receptors (IL‑6R), intracellular kinases involved in signal transduction pathways (JAKs, RIP1 kinase), transcription factors regulating gene expression during inflammation (NF-kB), and multiprotein complexes like inflammasomes—that collectively orchestrate leukocyte recruitment/activation and production of mediators responsible for tissue injury in diseases ranging from autoimmune disorders to chronic infections. Because this term does not specify any single molecule but rather encompasses numerous potential drug targets across different molecular families—including enzymes, receptors, ion channels, transporters—it cannot be mapped onto a unique canonical target entry suitable for structured databases focused on individual biomolecules.

Other names

Inhibition of inflammationAnti-inflammatory actionSuppression of inflammatory signaling

Drugs inhibit the inflammatory response by blocking pro-inflammatory cytokine signaling pathways; inhibiting leukocyte activation and chemotaxis; suppressing transcription factors like NF-kB; and antagonizing cell surface receptors involved in immune activation.